


# IRIS

### INSTITUTIONAL RESEARCH INFORMATION SYSTEM ARCHIVIO ISTITUZIONALE DEI PRODOTTI DELLA RICERCA

ntestazione	repositor	ydell'ateneo
IIICSIAZIONE	1 CPUSITOI	yucii alci icu

The protective effect of chondroitin sulfate on induced arthritis in rats.
This is a pre print version of the following article:
Original The protective effect of chondroitin sulfate on induced arthritis in rats. / Bauerova K.; Ponist S.; Mihalova D.; Paulovicova E.; Volpi N STAMPA (2010), pp. ND-ND. ((Intervento presentato al convegno OARSI 2010, world congress on osteoarthritis tenutosi a Brussel, Belgium nel 23-26 september 2010.
Availability: This version is available at: 11380/644730 since:
Publisher: Elsevier
Published DOI:
Terms of use: openAccess
Testo definito dall'ateneo relativo alle clausole di concessione d'uso
Publisher copyright

(Article begins on next page)



#### Cem Gabay, MD

Professor of Medicine
Director of the Division of Rheumatology
University Hospital
Geneva, Switzerland

### **Emmanuel Maheu, MD**


Assistant in Rheumatology, Rheumatology Department, St-Antoine Hospital, Paris, France

#### Daniel Uebelhart, MD

Assistant Professor Department of Rheumatology and Institute of Physical Medicine University Hospital Zürich, Switzerland

#### Nicola Volpi, Prof

Associate Professor of Biochemistry Faculty of Bioscience & Biotechnology Department of Biology University of Modena & Reggio Emilia Modena, Italy



## Achieving effective OA management: new insights for Chondroitin Sulfate

Chairman: Emmanuel Maheu (France)

- 12.30 Welcome and introduction
- 12.35 The protective effect of Chondroitin Sulfate on induced arthritis in rats
  Nicola Volpi (Italy)
- 12.55 Update on recommendations for the conduct of clinical trials in OA with a specific focus on hand OA

  Emmanuel Maheu (France)
- 13.15 FACTS: Finger osteoArthritis Chondroitin
  Treatment Study.
  The results of a randomized double-blind placebo
  controlled study with Chondroitin Sulfate
  in patients with hand osteoarthritis
  Cem Gabay (Switzerland)
- **13.35** Chondroitin Sulfate and its clinical evidences Daniel Uebelhart (Switzerland)
- 13.55 Discussion and conclusion
- 14.00 End of session